摘要
目的:观察健脾愈疡方联合雷贝拉唑三联疗法治疗消化性溃疡的临床效果。方法:选择消化性溃疡患者80例,按随机数字表法分为对照组和观察组各40例。对照组采用雷贝拉唑三联疗法,观察组在对照组基础上联合健脾愈疡方,治疗时间均为4周。观察2组临床疗效,比较2组患者的前列腺素E2(PGE2)、血管内皮生长因子(VEGF)、表皮生长因子(EGF)表达水平,并记录不良反应和治疗后3个月的溃疡复发率。结果:观察组总有效率为95.0%,高于对照组85.0%,差异有统计学意义(P<0.05)。治疗前,2组各项症状评分比较,差异无统计学意义(P>0.05)。治疗后,2组胃脘疼痛、嗳气吞酸、口干口苦、大便不调症状评分较治疗前降低(P<0.05),且观察组各项症状评分均低于对照组(P<0.05)。治疗前,2组血清PGE2、VEGF、EGF水平比较,差异无统计学意义(P>0.05)。治疗后,2组血清PGE2、VEGF、EGF水平较治疗前升高(P<0.05);且观察组血清PGE2、VEGF、EGF水平高于对照组(P<0.05)。观察组不良反应发生率为5.0%,低于对照组17.5%,差异有统计学意义(P<0.05)。观察组溃疡复发率为5.0%,低于对照组15.0%,差异有统计学意义(P<0.05)。结论:健脾愈疡方联合雷贝拉唑三联疗法治疗消化性溃疡的临床疗效显著,值得临床上推广运用。
Objective:To observe the clinical effect of Jianpi Yuyang prescription combined with rabeprazole triple therapy for peptic ulcer.Methods:A total of 80 cases of patients with peptic ulcer were selected,and divided into the control group and the observation group according to the random number table method,40 cases in each group.The control group was treated with rabeprazole triple therapy,and the observation group was additionally given Jianpi Yuyang prescription based on the treatment of the control group.Both groups were treated for four weeks.The clinical effect in the two groups was observed,the expression levels of prostaglandin E2(PGE2),vascular endothelial growth factor(VEGF)and epidermal growth factor(EGF)in the two groups were compared,and the adverse reactions as well as the recurrence rate of ulcer in three months after treatment were recorded.Results:The total effective rate was 95.0%in the observation group,higher than that of 85.0%in the control group,the difference being significant(P<0.05).Before treatment,there was no significant difference being found in the comparison of the symptom scores between the two groups(P>0.05).After treatment,the scores of symptoms including stomachache,belching and gastric discomfort with acid regurgitation,dry mouth and bitter taste,and abnormal defecation in the two groups were decreased when compared with those before treatment(P<0.05),and the scores of all the above symptoms in the observation group were lower than those in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of the levels of PGE2,VEGF and EGF in serum between the two groups(P>0.05).After treatment,the above levels in the two groups were increased when compared with those before treatment(P<0.05);the above levels in the observation group were higher than those in the control group(P<0.05).The incidence of adverse reactions was 5.0%in the observation group,lower than that of 17.5%in the control group,the difference being significant(P<0.05).The recurrence rate of ulcer was 5.0%in the observation group,lower than that of 15.0%in the control group,the difference being significant(P<0.05).Conclusion:The therapy of Jianpi Yuyang prescription combined with rabeprazole triple therapy has significant clinical effect in treating peptic ulcer,which is worthy of clinical promotion and application.
作者
卞银燕
王玉宗
徐燕芳
童晓群
BIAN Yinyan;WANG Yuzong;XU Yanfang;TONG Xiaoqun
出处
《新中医》
CAS
2020年第9期70-73,共4页
New Chinese Medicine
关键词
消化性溃疡
健脾愈疡方
雷贝拉唑三联疗法
前列腺素E2
血管内皮生长因子
表皮生长因子
Peptic ulcer
Jianpi Yuyang prescription
Rabeprazole triple therapy
Prostaglandin E2
Vascular endothelial growth factor
Epidermal growth factor
